Subsidiary of Lionco Pharmaceutical Group (603669.SH), L-carnitine injection has passed the consistency evaluation of generic drugs.

Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Melanske Pharmaceutical Co., Ltd. (hereinafter referred to as "Melanske"), has recently received the approval notice for the supplementary application of "Levocarnitine Injection" issued by the National Medical Products Administration. The drug has passed the evaluation of generic drug quality and efficacy consistency. Levocarnitine injection is mainly used for chronic kidney failure patients undergoing long-term hemodialysis who exhibit a series of complications due to secondary carnitine deficiency, such as cardiomyopathy, skeletal muscle disease, arrhythmia, hyperlipidemia, as well as hypotension and muscle spasms during dialysis. The evaluation of generic drug consistency for the company's Levocarnitine injection will enhance the drug's market competitiveness and have a positive impact on its market sales. It also accumulates valuable experience for the company's future products to undergo generic drug consistency evaluation.